The initial stage of development of AIDS Research at CWRU was characterized by extensive growth along areas of institutional strength (international aspects of AIDS, mycobacterial research), commitment of resources to develop molecular virology and essential core services such as the BL-3 facility, coordination of clinical care and research in a single unit, and training individuals with a variety of backgrounds to participate in AIDS Research. The proposed CFAR will allow a second phase of development, a crystallization of efforts through a central administrative structure and development of state-of-the-art cores that will allow an expanded research agenda. At this particular stage in evolution of AIDs research at CWRU, the Developmental Core is particularly important from two standpoints. The first is that effective use of this funding will allow coordinated development of research activities to promote optimal utilization of the CFAR core facilities. The second, and a distinctive feature of the CWRU CFAR, will be directed application of the developmental finding to enhance collaboration between basic and clinical scientists. The following is the rationale for utilization of development funds. Year 01 will be an important year for development of core facilities and enhancement of interdisciplinary research among investigators at CWRU. Two pilot projects will be supported in year 01 ($40,000 each). In year 02, funds are requested for four pilot projects ($40,000 each). Two pilot projects will be supported in year 03, three in year 04 and four in year 05, all at $40,000 each. Funds committed by the Internal Advisory Committee for evolving research opportunities will be obtained from the budget set aside for pilot projects. A new investigator will be recruited to start in year 03; salary support ($50,000 per year) and start-up funds ($80,000 year 03, $40,000 per year in years 04 and 05) will be committed for three years.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-02
Application #
3727720
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216
Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552

Showing the most recent 10 out of 539 publications